Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension

Aubrey de Grey — How close are we to robust mouse rejuvenation, and why does that matter?

Full talk at Future Day 2026 — link in reply 🔗

Polymath and trailblazer in bio-rejuvenation Aubrey de Grey gave a talk at Future Day 2026 on the next phase of robust mouse rejuvenation trials!

Synopsis: The “damage repair” approach to bringing aging under medical control has made huge strides since I first proposed it 25 years ago. However, since it is a divide-and-conquer strategy, we should not be surprised at the absence of progress in the “bottom line” of life extension, even in mice. Can we realistically expect that to change any time soon? I will present reasons to believe that we can, in the form of accelerating progress in proofs of efficacy of individual treatments, together with initial proof of concept that combining damage repair modalities will give additive benefits.

0:00 Intro.
0:29 Talk starts.
1:28 Age related vs infectious diseases.
3:26Epidemic of the chronic conditions of late life — why?
4:42 Ways to be sick: popular view.
7:10 Aging in three words (metabolism, damage, pathology)
11:46 Ways to be sick: correct view.
15:29 What we do these days against aging — Geriatrics.
18:21 Gerontology: A more promising approach?
20:57 Metabolism is complex.
22:37 Maintenance: A common sense alternative.
24:39 Comparison: car maintenance.
26:00 7 deadly things.
29:17 Cell 153:1194 — too many citations to count.
30:22 The first round of the race to RMR (Robust Mouse Rejuvenation)
38:43 Females: yay, additivity!
40:09 Males: messier, but mostly the same story.
41:02 What health indices did we measure?
43:23 RMR2: ASAP! See levf.org/rmr2
46:30 AUBRAI
48:36 Learn more and help!
51:11 How has the longevity industry vibe changed over the last 7 years?
56:32 LEV Foundation only org working on this combination of damage repair regimes.
57:55 Has AI made progress in helping solve aging? In-silico medicine.
1:01:16 Changes to seven deadly things?
1:04:54 Hallmarks of aging — defacto taxonomy — difficulty translating to other taxonomies?
1:06:17 Has the damage repair methodology been attracting people over?
1:09:56 Stradelling both academia and private industry — but what about the state?
1:13:36 Robust Mouse Rejuvenation timelines under ideal funding.
1:19:49 Infections.
1:25:46 Treatment cadence.

#rejuvenation #medicine #health #aging #ageing.

Continue reading “Aubrey de Grey — How close are we to robust mouse rejuvenation, and why does that matter?” | >

A World Where Anyone Who Needs a Bone Marrow Transplant Gets One — Kevin Caldwell — Ossium Health

Imagine a world where anyone who needs a bone marrow transplant can get one — on demand. No more desperate donor searches or deadly delays. Kevin Caldwell, Co-Founder & CEO, Ossium Health.

Bone marrow transplants have always depended on finding the right donor at the right time. But what if bone marrow could be stored, shipped, and used on demand—just like a drug? That’s exactly what Ossium Health is now showing in human clinical data.

Kevin Caldwell is the Co-Founder, CEO, and President of Ossium Health (https://ossiumhealth.com/), a clinical-stage bioengineering company pioneering off-the-shelf, cryopreserved bone marrow therapies derived from deceased organ donors.

Under Kevin’s leadership, Ossium has developed a novel platform designed to solve one of the most persistent challenges in transplantation medicine: timely access to compatible bone marrow for patients with life-threatening hematologic malignancies such as Acute Myeloid Leukemia. The company’s approach enables on-demand delivery of viable marrow cells, bypassing the logistical and biological constraints of traditional donor matching and scheduling.

Since its founding, Kevin has scaled Ossium from an early-stage startup into a clinical-stage company with a robust network of over 50 strategic partnerships across supply, clinical development, and commercial channels. He has led multiple financings and secured a landmark contract with the Biomedical Advanced Research and Development Authority, validating Ossium’s relevance to national health preparedness and biomanufacturing resilience.

Continue reading “A World Where Anyone Who Needs a Bone Marrow Transplant Gets One — Kevin Caldwell — Ossium Health” | >

Senescence at the crossroads of postpartum remodeling and tumorigenesis

Cellular senescence has been linked to both beneficial and detrimental functions. Chiche, Djoual, Charifou and colleagues show that senescence supports normal postpartum mammary gland remodeling, but that when oncogenic events coincide with involution, senescent cells enhance tumorigenesis by regulating plasticity, invasion and metastasis.

AI Designed Peptides Could Cure… EVERYTHING. LigandForge Is Here

LigandForge generates 150,000 peptide drug candidates in 3 minutes — a million times faster than existing methods, unlocking a tsunami of possible treatments.

A man with no medical background used ChatGPT, AlphaFold, and Grok to design a custom mRNA cancer vaccine for his dying dog — and her biggest tumor shrank 75%.

Meanwhile, scientists discovered a single protein that literally spreads aging through your bloodstream. These stories are each incredible on their own. But the big story is the implications for curing aging.

In this deep dive, I break down how these three breakthroughs fit together, what peptides and mRNA vaccines actually are (and how they’re different), and why this moment might be the most important inflection point in the history of drug design.

The age of custom AI cures isn’t coming. It’s here.

HUME BODY POD DISCOUNT UP TO 50% OFF:

Continue reading “AI Designed Peptides Could Cure… EVERYTHING. LigandForge Is Here” | >

Unraveling the secrets of telomerase, an enzyme linked to aging and cancer

A central question in molecular biology is how cells protect their chromosomes from damage during repeated cell division. At the heart of this protective process is an enzyme called telomerase. Now an international research team has mapped the three-dimensional structure of telomerase in the yeast Saccharomyces cerevisiae, a widely used model organism in genetics.

Using cutting-edge technology, the scientists were able to visualize the architecture of this complex enzyme in unprecedented detail, uncovering unexpected features that may explain how it functions.

This major discovery was the result of an international collaboration between Pascal Chartrand, a professor in the Department of Biochemistry and Molecular Medicine at Université de Montréal, and researchers from Université de Sherbrooke and the MRC Laboratory of Molecular Biology in the U.K. Their findings were recently published in Science.

What changes happen in the aging brain?

A new study from the Salk Institute maps how the aging brain changes at the epigenetic level — cell type by cell type.

The researchers created one of the most detailed single-cell atlases yet of the aging mouse brain, spanning 8 brain regions, 36 cell types, and hundreds of thousands of cells. They found major age-related changes in DNA methylation, chromatin structure, and gene activity, with some of the strongest changes appearing in non-neuronal cells.

This kind of work matters because it moves brain aging closer to mechanism — not just describing decline, but identifying the molecular regulatory shifts that may drive vulnerability to neurodegenerative disease.

Highlights Salk researchers create epigenetic atlas of cell type-specific changes in the aging mouse brain The atlas represents eight different brain regions and 36 different cell types, and shows clear epigenetic differences associated with different ages The new resource—available publicly on Amazon Web services—can be used to unravel age-related contributions to neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS LA JOLLA—Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer’s to Parkinson’s to ALS and beyond, is expected to double every 20 years. Though scientists know aging is a major risk factor for neurodegenerative diseases, the full mechanisms behind aging’s impact remain unclear.

/* */